ACCIDENT & EMERGENCY
technologies that power Amazon Alexa. Novo Nordisk and Glooko’s
Cornerstones4Care powered by the Glooko app (C4C app) and Roche’s app, mySugr, also help people to more effectively manage their diabetes. Sanofi and Voluntis’ app focuses on digital insulin titration solutions, which will help type 2 diabetes (T2D) patients on basal insulin improve their self-management. In order to help improve the identification
of AF, AliveCor’s platform, Kardia Pro, incorporates artificial intelligence (AI), while BioSig Technologies – in partnership with the Mayo Clinic – is developing the PURE EP cardiac signal acquisition and display platform to assist with the diagnosis and treatment of complex arrhythmias. The American Heart Association (AHA) teamed up with IBM Watson Health, the cognitive system division of IBM Corporation. AHA’s science-based metrics and health assessments will be combined with IBM’s cognitive analytics and the system will be delivered on Welltok’s health optimisation app platform.
Google’s former life-science arm, Verily, has
initiated Project Baseline, a study with 10,000 participants to gain a better understanding of the physical and biochemical predisposition to various illnesses. The company will be using its proprietary technology, a sensor-based smart watch designed to capture a huge volume of data. Participants will be wearing this watch on a daily basis and will also have their whole genomes sequenced and various
biospecimens taken. Their behaviour, including social media activity, will also be monitored. MannKind and OneDrop are collaborating
on the A-ONE study, a randomized controlled trial investigating the use of Afrezza (inhaled technosphere insulin) with an integrated digital diabetes care platform that could potentially deliver improved health outcomes in a more cost-effective way compared to standards of care. Treatment adherence and cardiovascular lifestyle changes are key to secondary prevention in patients with myocardial infarction (MI). AstraZeneca and Scientific Med AB are collaborating on the SUPPORT study to evaluate the potential of mobile- phone-based interactive patient support tools to improve adherence regarding drug treatment and lifestyle modifications in patients diagnosed with MI.
CVMD digital health technology
Innovative digital health technology will provide invaluable patient information and insights that could improve individualised patient care while reducing healthcare cost; however, effective adoption and implementation of digital health technologies is key to success. Attributes of ideal digital health technology in CVMD include: unobtrusive monitoring systems that deliver useful and meaningful data that impact patient management, combining data analytics with AI for improved diagnosis and treatment plans, user-friendly technologies with easy-to-interpret data, and
cost-effective technologies that support management, lifestyle modification, and patient compliance. Kovalcsik added: ‘‘The ability to reduce hospital admissions and mortality in patients with CV disease and/or patients with implanted cardiac devices, and the capability to recognise and proactively prevent CV and metabolic diseases, could mean a better quality of life for these patients and reduced healthcare cost in the CVMD space.’’
What of the future?
Josh Hughes recently wrote about the legal implications of driverless car technology upon the personal injury world. He concluded that, regardless of the benefits of the technology, unless parents are willing to let their children travel in driverless cars, it wouldn’t get off the ground.
“In much the same way, AI use in medicine will be restricted unless the medical profession and patients trust it,” he observed. “Part of this is ensuring that a victim has a clear path of redress when things go wrong. “In obtaining this trust, the industry – including those tasked with regulating, testing and monitoring service delivery – will need to work closely with those pioneering AI. Done properly, technological advancement is likely to benefit doctors and patients alike.” A geneticist John Bell told the BBC: “At the NHS, about £2.2 billion is being used for pathology. In fact, 50% may be possible to save. AI may be the NHS’ saviour.” CSJ
ClinicalEngineeringConfeference Wherewe areTodayTo ay? Tuesday
Tu Wo
Need a bin? We’ve got just the thing Flip, swing or multi-compartment, innovative all-plastic sack holders to sustainable hardwood external bins.
Call us now on 01684 295782
www.trojanbins.com
JUNE 2018
sales@trojanbins.com ay18th September 2018
Wolverhampton Race course This is an annual one day
Phone: 01245 544600
Email:
gemma.aitchison@
npag.eastamb.nhs.uk National Performance Advisory Group
East of England Ambulance Service NHS Trust Orchards, Broomfield, Chelmsford, Essex CM1 7WS
Follow us @NPAGUK
WWW.CLINICALSERVICESJOURNAL.COM I 77 into issues that are currently being talked about today. y.
ay conference that will give new insights ay
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
